Adjuvant hormone therapy after radiation or surgery for localized or locally advanced prostate cancer

Current Treatment Options in Oncology

Volumn 4, Issue 5, 2003, Pages 351-362

  See, William A ^a  

^a FROEDTERT MEMORIAL LUTHERAN HOSPITAL   (United States)

Author keywords

Advanced Prostate Cancer; Flutamide; Goserelin; Main Drug Interaction; Radical Prostatectomy

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADJUVANT CHEMOTHERAPY; AGED; CANCER INVASION; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; SURVIVAL; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY, NEEDLE; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0142244519     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-003-0036-5     Document Type: Article

References (48)

1. Mettlin CJ, Murphy GP, Rosenthal DS, Menck HR: The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer 1998, 83:1679–1684. DOI: 10.1002/(SICI)1097-0142(19981015)83:8<1679::AID-CNCR24>3.0.CO;2-Y
2. Jemal A, Murray T, Samuels A, et al.: Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5–26.
3. D'Amico AV, Whittington R, Malkowicz SB, et al.: Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 2002, 95:281–286. DOI: 10.1002/cncr.10657
4. Kupelian PA, Elshaikh M, Reddy CA, et al.: Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single- institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 2002, 20:3376–3385. DOI: 10.1200/JCO.2002.01.150
5. Huggins C, Hodges CV: Studies on prostatic cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293–297.
6. Pollack A, Zagars GK, Kopplin S: Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1995, 32:13–20. DOI: 10.1016/0360-3016(94)00450-Y
7. Kirby R: Treatment options for early prostate cancer. Urology 1998, 52:948–962. DOI: 10.1016/S0090-4295(98)00428-2
8. Ross RW, Small EJ: Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol 2002, 167:1952–1956. DOI: 10.1016/S0022-5347(05)65060-4
9. Green HJ, Pakenham KI, Headley BC, et al.: Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial. BJU Int 2002, 90:427–432. DOI: 10.1046/j.1464-410X.2002.02917.x
10. Fonseca R, Rajkumar SV, White WL, et al.: Anemia after orchiectomy. Am J Hematol 1998, 59:230–233. DOI: 10.1002/(SICI)1096-8652(199811)59:3<230::AID-AJH8>3.0.CO;2-2
11. Basaria S, Lieb J, Tang AM, et al.: Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) 2002, 56:779–786. DOI: 10.1046/j.1365-2265.2002.01551.x
12. Granfors T, Modig H, Damber JE, Tomic R: Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. J Urol 1998, 159:2030–2034. DOI: 10.1016/S0022-5347(01)63235-X
13. Messing EM, Manola J, Sarosdy M, et al.: Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781–1788. This trial showed that adjuvant hormone therapy achieved by bilateral orchiectomy or the LHRH agonist goserelin significantly improves disease-free and overall survival after radical prostatectomy in patients with node-positive prostate cancer. DOI: 10.1056/NEJM199912093412401
14. Bolla M, Collette L, Blank L, et al.: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103–108. A clinical trial showing that adjuvant therapy with the LHRH agonist goserelin, administered for 3 years after external irradiation, improves disease-free and overall survival in patients with locally advanced prostate cancer. DOI: 10.1016/S0140-6736(02)09408-4
15. Cassileth BR, Soloway MS, Vogelzang NJ, et al.: Patients' choice of treatment in stage D prostate cancer. Urology 1989, 33(Suppl):57–62. DOI: 10.1016/0090-4295(89)90108-8
16. Bruchovsky N, Goldenberg SL, Akakura K, Rennie PS: Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol. Cancer 1993, 72:1685–1691. DOI: 10.1002/1097-0142(19930901)72:5<1685::AID-CNCR2820720532>3.0.CO;2-3
17. Vogelzang NJ, Chodak GW, Soloway MS, et al.: Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Urology 1995, 46:220–226. DOI: 10.1016/S0090-4295(99)80197-6
18. Prayer-Galetti T, Zattoni F, Capizzi A, et al.: Disease free survival in patients with pathological "C stage" prostate cancer at radical retropubic prostatectomy submitted to adjuvant hormonal treatment. Eur Urol 2000, 38:504.
19. Lawton CA, Winter K, Murray K, et al.: Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 49:937–946. A clinical trial showing that long-term therapy with the LHRH agonist goserelin after external irradiation improves diseasefree survival in patients with locally advanced prostate cancer. For patients who did not undergo radical prostatectomy and who had a Gleason score of 8 to 10, adjuvant goserelin significantly improved overall and cause-specific survival. DOI: 10.1016/S0360-3016(00)01516-9
20. Hanks GE, Lu J, Machtay V, et al.: RTOG protocol 92-02: a phase III trial of the use of long term androgen suppression following neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate [abstract]. Proc Am Soc Clin Oncol 2000, 19:327a.
21. Pilepich MV, Caplan R, Byhardt RW, et al.: Phase III trial of androgen suppression using goserelin in unfavorable- prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J Clin Oncol 1997, 15:1013–1021.
22. Bolla M, Gonzalez D, Warde P, et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295–300. DOI: 10.1056/NEJM199707313370502
23. Neymark N, Adriaenssen I, Gorlia T, et al.: Cost effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer: results decisively determined by the cut-off time-point chosen for the analysis. Eur J Cancer 2001, 37:1768–1774. DOI: 10.1016/S0959-8049(01)00197-6
24. Persad R: Leuprorelin acetate in prostate cancer: a European update. Int J Clin Pract 2002, 56:389–396.
25. Parmar H, Edwards L, Phillips RH, et al.: Orchiectomy versus long-acting D-Trp-6-LHRH in advanced prostatic cancer. Br J Urol 1987, 59:248–254.
26. Brogden RN, Chrisp P: Flutamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in advanced prostatic cancer. Drugs Aging 1991, 1:104–115.
27. Schröder FH, Collette L, De Reijke TM, et al.: Prostate cancer treated by anti-androgens: is sexual function preserved? Br J Cancer 2000, 82:283–290. DOI: 10.1054/bjoc.1999.0916
28. Gillatt DA, Bolton CH, Chadwick D, et al.: Lipoprotein levels following treatment with cyproterone acetate or LHRH analogues. Br J Urol 1993, 71:728–730.
29. de Voogt HJ, Smith PH, Pavone-Macaluso M, et al.: Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J Urol 1986, 135:303–307.
30. Pinganaud G, Chaslerie A, Bourdel Marchasson I, et al.: Cyproterone-induced hepatotoxicity. Ann Pharmacother 1995, 29:634.
31. Kolvenbag GJ, Iversen P, Newling DW: Antiandrogen monotherapy: a new form of treatment for patients with prostate cancer. Urology 2001, 58(Suppl 2A):16–23. DOI: 10.1016/S0090-4295(01)01237-7
32. Iversen P, Tyrrell CJ, Kaisary AV, et al.: Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of follow-up. J Urol 2000, 164:1579–1582. DOI: 10.1016/S0022-5347(05)67032-2
33. McLeod DG: Tolerability of nonsteroidal antiandrogens in the treatment of advanced prostate cancer. Oncologist 1997, 2:18–27.
34. See WA, Wirth MP, McLeod DG, et al.: Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the Early Prostate Cancer program. J Urol 2002, 168:429–435. This is the first report of the Early Prostate Cancer program involving bicalutamide 150 mg, the largest treatment program in early prostate cancer. At this first analysis, adjuvant bicalutamide 150 mg after radical prostatectomy or radiotherapy significantly reduced the risk of objective disease progression in men with localized or locally advanced prostate cancer. DOI: 10.1016/S0022-5347(05)64652-6
35. See W, McLeod D, Iversen P, Wirth M: The bicalutamide Early Prostate Cancer program: demography. Urol Oncol 2001, 6:43–47. DOI: 10.1016/S1078-1439(00)00118-6
36. See W, Wirth M, McLeod D, et al.: Immediate treatment with bicalutamide reduces the risk of disease progression in early non-metastatic prostate cancer irrespective of primary therapy. Eur Urol Suppl 2002, 1:136. DOI: 10.1016/S1569-9056(02)80526-7
37. Wirth M, Frohmüller H, Marx F, et al.: Randomized multicenter trial on adjuvant flutamide therapy in locally advanced prostate cancer after radical surgery: interim analysis of treatment effect and prognostic factors [abstract]. Br J Urol 1997, 80(Suppl 2):1033a.
38. Wirth M, Froehner M: A review of studies of hormonal adjuvant therapy in prostate cancer. Eur Urol 1999, 36(Suppl 2):14–19. DOI: 10.1159/000052338
39. Tyrell C, Morris T, Carroll K: Prophylactic breast irradiation significantly reduces the incidence of bicalutamide- induced gynaecomastia. Eur Urol 2002, 1:136.
40. Saltzstein D, Cantwell A, Sieber P, et al.: Prophylactic tamoxifen significantly reduces the incidence of bicalutamide-induced gynaecomastia and breast pain. BJU Int 2002, 90(Suppl 2):120–121.
41. Decensi AU, Boccardo F, Guarneri D, et al.: Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. J Urol 1991, 146:377–381.
42. Schmitt B, Wilt TJ, Schellhammer PF, et al.: Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology 2001, 57:727–732. DOI: 10.1016/S0090-4295(00)01086-4
43. Klotz L: Combined androgen blockade in prostate cancer: meta-analyses and associated issues. BJU Int 2001, 87:806–813. DOI: 10.1046/j.1464-410x.2001.02184.x
44. Trachtenberg J, Gittleman M, Steidle C, et al.: A phase 3 multicenter open label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 2002, 167:1670–1674. DOI: 10.1097/00005392-200204000-00021
45. Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988, 7:165–170.
46. Hedlund PO, Henriksson P: Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. Urology 2000, 55:328–333. DOI: 10.1016/S0090-4295(99)00580-4
47. Ockrim JL, Lalani EN, Laniado ME, et al.: Transdermal estrogen therapy for advanced prostate cancer: forward to the past? J Urol 2002, 167:175.
48. Waymont B, Lynch TH, Dunn JA, et al.: Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 1992, 69:614–620. DOI: 10.1111/j.1464-410X.1992.tb15633.x